Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “sector perform” rating reiterated by equities researchers at Royal Bank of Canada in a note issued to investors on Monday, Benzinga reports. They currently have a $74.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of 6.37% from the company’s previous close.
A number of other equities analysts have also issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Maxim Group reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Morgan Stanley dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $83.47.
Get Our Latest Analysis on Gilead Sciences
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.37 earnings per share. Research analysts forecast that Gilead Sciences will post 3.75 EPS for the current year.
Institutional Trading of Gilead Sciences
A number of large investors have recently added to or reduced their stakes in GILD. Schonfeld Strategic Advisors LLC acquired a new stake in Gilead Sciences in the third quarter valued at $896,000. Truist Financial Corp raised its position in shares of Gilead Sciences by 1.4% in the third quarter. Truist Financial Corp now owns 573,445 shares of the biopharmaceutical company’s stock valued at $42,974,000 after purchasing an additional 7,890 shares during the period. Axxcess Wealth Management LLC raised its position in shares of Gilead Sciences by 61.5% in the third quarter. Axxcess Wealth Management LLC now owns 14,899 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 5,674 shares during the period. Ameriprise Financial Inc. raised its position in shares of Gilead Sciences by 7.3% in the third quarter. Ameriprise Financial Inc. now owns 1,703,783 shares of the biopharmaceutical company’s stock valued at $127,675,000 after purchasing an additional 115,189 shares during the period. Finally, EHP Funds Inc. raised its position in shares of Gilead Sciences by 20.6% in the third quarter. EHP Funds Inc. now owns 14,900 shares of the biopharmaceutical company’s stock valued at $1,117,000 after purchasing an additional 2,550 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
- Five stocks we like better than Gilead Sciences
- Profitably Trade Stocks at 52-Week Highs
- Applied Digital Boosts Stock with Cutting-Edge AI Data Centers
- Conference Calls and Individual Investors
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- How to Invest in Gold: A Complete Guide
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.